DCOY

Decoy Therapeutics Inc.
CAPPED RATING

Decoy Therapeutics Inc. (DCOY) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (F). The rating has held at C- for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B
Factor Score 3.5 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
F
Factor Score 0.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.1
EV / EBITDA 1.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -69.2%
Price Return 12M -96.2%
Catalyst Signal 0.00
Market Cap $2.6M
TTM Revenue $227.6K
Price / Sales 11.6
ROE N/M

Historical Factor Score Progression

Held C- for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B (3.5) C- (2.0) D+ (1.8) F (0.5) C+ (2.6) C- (2.1)
2026-11-04 B (3.5) C- (2.0) D+ (1.8) F (0.4) C+ (2.7) C- (2.1)
2026-10-28 B (3.5) C- (1.9) D+ (1.8) F (0.5) C+ (2.7) C- (2.1)
2026-10-21 B (3.5) C- (1.9) D+ (1.8) F (0.5) C+ (2.6) C- (2.1)
2026-10-14 B (3.4) C- (1.9) D+ (1.8) F (0.5) C+ (2.6) C- (2.1)
Page 1 of 4